Codexis, Inc. (NASDAQ:CDXS – Get Rating) Director John J. Nicols sold 35,714 shares of the business’s stock in a transaction on Tuesday, January 24th. The shares were sold at an average price of $6.42, for a total transaction of $229,283.88. Following the transaction, the director now directly owns 823,750 shares in the company, valued at $5,288,475. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Codexis Stock Performance
Codexis stock traded up $0.26 during mid-day trading on Wednesday, reaching $6.61. The stock had a trading volume of 592,520 shares, compared to its average volume of 808,089. The company has a 50-day moving average price of $5.40 and a two-hundred day moving average price of $6.44. Codexis, Inc. has a one year low of $4.21 and a one year high of $22.22.
Codexis (NASDAQ:CDXS – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. The company had revenue of $34.47 million for the quarter, compared to analysts’ expectations of $31.41 million. Codexis had a negative net margin of 23.49% and a negative return on equity of 19.59%. Sell-side analysts anticipate that Codexis, Inc. will post -0.56 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Hedge Funds Weigh In On Codexis
Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Codexis by 20.5% during the 1st quarter. JPMorgan Chase & Co. now owns 52,116 shares of the biotechnology company’s stock valued at $1,075,000 after acquiring an additional 8,870 shares during the period. Bank of New York Mellon Corp lifted its stake in Codexis by 0.7% during the 1st quarter. Bank of New York Mellon Corp now owns 220,879 shares of the biotechnology company’s stock valued at $4,554,000 after acquiring an additional 1,618 shares during the period. US Bancorp DE lifted its stake in Codexis by 517.5% during the 1st quarter. US Bancorp DE now owns 8,380 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 7,023 shares during the period. MetLife Investment Management LLC lifted its stake in Codexis by 55.6% during the 1st quarter. MetLife Investment Management LLC now owns 32,963 shares of the biotechnology company’s stock valued at $680,000 after acquiring an additional 11,784 shares during the period. Finally, BlackRock Inc. lifted its stake in Codexis by 0.7% during the 1st quarter. BlackRock Inc. now owns 5,183,443 shares of the biotechnology company’s stock valued at $106,885,000 after acquiring an additional 38,494 shares during the period. Institutional investors own 93.41% of the company’s stock.
Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.
- Get a free copy of the StockNews.com research report on Codexis (CDXS)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.